<DOC>
	<DOCNO>NCT01287754</DOCNO>
	<brief_summary>This single arm , open-label study ass efficacy safety Tarceva ( erlotinib ) patient locally advanced metastatic non-small cell lung cancer epidermal growth factor receptor ( EGFR ) mutation . Patients receive Tarceva dose 150 mg daily orally disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Patients With Locally Advanced Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Locally advanced metastatic ( stage III/IV ) nonsmall cell lung cancer EGFR mutation Measurable disease accord RECIST criterion ECOG performance status 02 Adequate haematological , renal liver function Previous chemotherapy therapy EGFR metastatic disease History another malignancy , except situ carcinoma cervix , adequately treat basal cell skin carcinoma , radically treat prostate carcinoma good prognosis Symptomatic cerebral metastasis Preexisting parenchymal lung disease pulmonary fibrosis Concomitant use coumarins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>